Replies to post #767 on Oncternal Therapeutics Inc (ONCT)

[beaglehub]

Stopped for 2 reasons........although primary endpoints met and worked the results for SUI were better than expected so saving money to use on SUI ongoing trials and immuno-oncology is becoming new standard in treating cancer

[kmx_swing]

official company announcement...I follow the company

maybe you should do the same...if you are invested in this company or plan to do so...

Although both the 9 mg and 18 mg cohorts met the primary efficacy endpoint in the Phase 2 clinical trial, after evaluating the drug development environment for breast cancer, where treatment paradigms are shifting to immunotherapies and/or combination therapies, the Company has decided that the time and cost of conducting the necessary clinical trials for approval in this indication do not warrant further development of enobosarm in this indication at this time.